Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 13, 2014
06 Janvier 2014 - 2:00PM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will
host an investor webcast and conference call on Monday, January 13,
at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) coinciding with
the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco.
During the event, Portola's senior management team will provide an
update on the Company's recent business progress.
To access the live conference call, please dial (866) 318-8611
from the U.S. and Canada, or +1(617) 399-5130 internationally, and
use the passcode 26453758. Please dial in 10 minutes prior to the
start of the call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
company's website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary. A replay of the
webcast will be available on the Company's website for 30 days
following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company focused
on the development and commercialization of novel therapeutics in
the areas of thrombosis and hematology.
Betrixaban
Portola's wholly-owned lead compound, betrixaban, is a novel,
oral, once-daily Factor Xa inhibitor in Phase 3 development for
extended-duration prophylaxis of venous thromboembolism (VTE) in
acute medically ill patients. Betrixaban's properties may be
uniquely suited to potentially demonstrate efficacy without
significantly increasing bleeding in this patient population.
Currently, there is no anticoagulant approved for extended-duration
VTE prophylaxis in acute medically ill patients.
Andexanet Alfa* (PRT4445)
Portola's second lead development candidate, andexanet alfa
(PRT4445), has the potential to be a first-in-class universal
antidote to directly reverse the effects of Factor Xa inhibitors in
patients who suffer an uncontrolled bleeding episode or who require
emergency surgery. Portola retains full, worldwide commercial
rights to andexanet alfa, which has been designated as a
breakthrough therapy by the U.S. Food and Drug Administration.
Cerdulatinib* (PRT2070) and PRT2607
Portola's third product candidate, cerdulatinib (PRT2070), is an
orally available kinase inhibitor that uniquely inhibits two
validated tumor proliferation pathways -- spleen tyrosine kinase
(Syk) and janus kinase (JAK). It is currently being studied in
patients with genetically-defined hematologic cancers, as well as
for patients who have failed therapy due to relapse or acquired
mutations. Portola's fourth program is partnered with Biogen Idec
and is focused on the development of PRT2607, a selective Syk
inhibitor. For more information, visit www.portola.com.
Forward-looking statement
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements
regarding: Portola's plans for future clinical studies and
pursuit of an Accelerated Approval process for andexanet alfa,
anticipated growth in the market for anticoagulants, and the
potential efficacy, safety, and activity of andexanet alfa,
betrixaban, and cerdulatinib. Risks that contribute to the
uncertain nature of the forward-looking statements include: the
accuracy of Portola's estimates regarding its ability to initiate
and/or complete its clinical trials; the success of Portola's
clinical trials and the demonstrated efficacy of Portola's product
candidates thereunder; the accuracy of Portola's estimates
regarding its expenses and capital requirements; regulatory
developments in the United States and foreign countries; Portola's
ability to obtain and maintain intellectual property protection for
its product candidates; and the loss of key scientific or
management personnel. These and other risks and uncertainties are
described more fully in Portola's most recent filings with the
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Portola undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
*Andexanet alfa and cerdulatinib are proposed International
Nonproprietary Names (pINN).
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024